Clinical data | |
---|---|
Trade names | Metastat (proposed) |
ATC code |
|
Legal status | |
Legal status |
|
Identifiers | |
IUPAC name
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
KEGG | |
ChEMBL | |
Chemical and physical data | |
Formula | C19H17NO7 |
Molar mass | 371.345 g·mol |
3D model (JSmol) | |
SMILES
| |
InChI
|
Incyclinide (proposed trade name Metastat) is a chemically modified tetracycline antibiotic that was investigated in clinical trials for the treatment of rosacea, various tumours, allergic and inflammatory diseases and a number of other conditions.
Data from animal studies suggest that centrally infused incyclinide attenuates microglial mediated neuroinflammation in the paraventricular nucleus of the hypothalamus and sympathetic activation in angiotensin II-induced hypertension. This was also associated with unique changes in gut microbial communities and profound attenuation of gut pathology in animal models of hypertension.
Mechanism of action
Like other tetracyclines, incyclinide inhibits matrix metalloproteinases. In contrast to traditional tetracyclines, it lacks antibiotic properties.
References
- Reuters: CollaGenex says incyclinide ineffective for rosacea
- Spreitzer H (2 July 2007). "Neue Wirkstoffe - Incyclinid". Österreichische Apothekerzeitung (in German) (14/2007): 655.
- ClinicalTrials.gov: Incyclinide
- Sharma RK, Yang T, Oliveira AC, Lobaton GO, Aquino V, Kim S, et al. (March 2019). "Microglial Cells Impact Gut Microbiota and Gut Pathology in Angiotensin II-Induced Hypertension". Circulation Research. 124 (5): 727–736. doi:10.1161/CIRCRESAHA.118.313882. PMC 6395495. PMID 30612527.
- Viera MH, Perez OA, Berman B (2007). "Incyclinide". Drugs of the Future. 32 (3): 209–214. doi:10.1358/dof.2007.032.03.1083308.
This pharmacology-related article is a stub. You can help Misplaced Pages by expanding it. |